GlaxoSmithKline presented its latest clinical pipeline data and artificial-intelligence strategy at the Bernstein Insights Healthcare Leaders and Disruptors forum on Wednesday, spotlighting programs aimed at chronic obstructive pulmonary disease and inflammatory conditions.
Kaivan Khavandi, GSK's senior vice president and global head of translational and development sciences, outlined the company's respiratory, immunology and inflammation portfolio, which includes ultra-long-acting biologic programs targeting type 2 inflammatory pathways.
Extencha, a long-acting TSLP program currently in Phase III for COPD, seeks to extend dosing intervals beyond current options. A separate GSK995 program targets IL-33 and is designed for quarterly administration. Data from the NAZARE Phase II asthma study was cited as confirming the pharmacology needed to support twice-yearly dosing for the TSLP asset class.
COPD affects an estimated 300 million patients globally. Khavandi noted the company is stratifying patients by eosinophil count—above 300 cells indicating Th2-driven disease, 150 to 300 as intermediate, and below 150 as Th2-low—to tailor therapeutic approaches.
GSK also discussed HS235, an activin trap asset acquired from Tris Pharma. Multiple ascending-dose studies showed no adverse events of concern over a 20-week period, according to the company. The firm previously acquired FGF21 assets from Boston Pharmaceuticals, expanding its metabolic and fibrosis research platform.
Competitive dynamics in the TSLP space were acknowledged. Roche's astegolimab demonstrated a 15 percent annualized exacerbation reduction in clinical data, while Sanofi's itepekimab and Regeneron's tozorakimab are also under development. Existing approved therapies such as Dupekent and Nucala remain central to GSK's respiratory franchise.
Khavandi drew an analogy to heart failure therapeutics when discussing the limitations of symptomatic treatments. "Diuretics make you feel great. They do not make you live longer," he said, underscoring the importance of disease-modifying approaches in chronic conditions.
On Wednesday, GSK shares closed at $49.71, down 1.99 percent, within a 52-week range of $39.29 to $61.70. The company holds a market capitalization of approximately $101 billion, a price-to-earnings ratio of 16.05 and a dividend yield of 3.5 percent. Analyst price targets cited at the forum ranged from $50 to $70. GSK is scheduled to report third-quarter earnings on October 28, 2026.
